Sevres

Researchers are evaluating two psycho-physical interventions for people with moderate to severe alcohol use disorder AUD to reduce heavy drinking days and prevent relapse. The study compares Mindfulness Based Relapse Prevention MBRP, a structured program involving mindfulness practice, with an unguided meditative relaxation program. This research addresses the need for effective therapies in AUD, as only a small percentage of patients receive approved drugs, and some patients are resistant to cognitive behavioral therapies. Participants will be randomly assigned to either the MBRP group or a relaxationmeditation control group. MBRP involves seven sessions lasting 60 to 120 minutes each, covering topics such as triggers, relapse prevention, and mindfulness in daily life, including meditation exercises and discussions on at-home practice. The relaxation group attends seven sessions of unguided relaxation with nature sounds, accommodating up to 12 participants per group. Throughout the study, participants will be monitored for changes in heavy drinking days, alcohol consumption, craving frequency and strength, anxiety, depression, quality of life, emotion regulation, impulsivity, coping mechanisms, and cognitive impairment over 3, 6, and 12 months. Researchers will track the number of meditation sessions and assess mental health and behavioral changes. The primary outcome is the reduction in heavy drinking days six months after inclusion, with continued evaluations up to one year.

Researchers are studying a group of 250 people who carry a germline GATA2 mutation to understand factors that predict changes in their blood cell populations over time. This includes both retrospective cases of people who have passed away or lost follow-up and prospective cases of living patients newly or previously identified with this mutation. The study aims to track the timing of specific clinical events related to this mutation over five years. The study involves collecting biological samples such as blood and bone marrow from the prospective participants during routine care visits over five years, with no extra samples taken beyond standard practice. Retrospective participants archived samples will also be analyzed. The study is open-label and conducted across multiple sites, including both retrospective and prospective cohorts. Participants will be monitored through their regular medical care, with sample collection aligned to usual practice schedules. Researchers will measure the time from birth to the onset of various clinical events associated with the mutation, including hematological events and disease progression. Data from both living and deceased patients will be used to understand disease evolution and outcomes over a long-term period.